97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing

ABSTRACT IMPACT: The implementation of DPYD and UGT1A1 pharmacogenetic testing, a promising tool of precision medicine, translates evidence-based research into clinical oncology practice with personalized dosing to better predict interpatient variability in chemotherapy tolerability. OBJECTIVES/GOAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Varughese, Lisa A., Lau-Min, Kelsey S., Teitelbaum, Ursina, Osei-Akoto, AnnaClaire, Reddy, Nandi, Damjanov, Nevena, Massa, Ryan, Tuteja, Sony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Precision Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827955/
http://dx.doi.org/10.1017/cts.2021.666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827955/
http://dx.doi.org/10.1017/cts.2021.666

Ejemplares similares